Peramivir use for treatment of hospitalized patients with influenza a(H1N1)pdm09 under emergency use authorization, october 2009-june 2010

Clinical Infectious Diseases

Volumn 55, Issue 1, 2012, Pages 8-15

  Yu, Yon ^a   Garg, Shikha ^b   Yu, Patricia A ^a   Kim, Hye Joo ^a   Patel, Anita ^c   Merlin, Toby ^a   Redd, Stephen ^d   Uyeki, Timothy M ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Division of Strategic National Stockpile   (United States)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERAMIVIR;

ADOLESCENT; ADULT; AGED; BRADYCARDIA; CHILD; CONTROLLED STUDY; CONVULSION; DRUG FATALITY; DRUG HYPERSENSITIVITY; ELECTRONIC MEDICAL RECORD; EMERGENCY TREATMENT; FEMALE; GRAND MAL SEIZURE; HEALTH CARE SURVEY; HOSPITAL PATIENT; HUMAN; HYPERTRANSAMINASEMIA; INFANT; INFLUENZA A; INFLUENZA A (H1N1); INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEWBORN; PANDEMIC INFLUENZA; PNEUMOTHORAX; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RHABDOMYOLYSIS; SCHOOL CHILD; STROKE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; DRUG UTILIZATION; EMERGENCY TREATMENT; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; UNITED STATES;

EID: 84862183539     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis352     Document Type: Review

References (27)

1. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
2. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-15.
3. Food and Drug Administration. Oseltamivir Emergency Use Authorization. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM143872.pdf. Accessed 1 February 2012.
4. Food and Drug Administration. Zanamivir Emergency Use Authorization. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM143854.pdf. Accessed 1 February 2012.
5. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-63.
6. Giraud C, Manceau S, Oualha M, et al. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Antimicrob Agents Chemother 2011; 55:433-5.
7. Wildschut ED, de Hoog M, Ahsman MJ, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One 2010; 5: e10938.
8. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.
9. GlaxoSmithKline. Relenza prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021036s019lbl. pdf. Accessed 30 December 2011.
10. Food and Drug Administration. Safety alert for Relenza (zanamivir) inhalation powder. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081. htm. Accessed 30 December 2011.
11. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361: 2204-7.
12. Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the Emergency Use Authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther 2010; 88: 587-9.
13. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
14. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-74.
15. Food and Drug Administration. Peramivir EUA Fact Sheet for Health Care Providers [amended 19 November 2010]. Available at: http://www.fda.gov/ downloads/Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/UCM187811.pdf. Accessed 19 May 2011.
16. Food and Drug Administration. Peramivir Letter of Authorization. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/UCM187800.pdf Accessed 19 May 2011.
17. Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev 1995; 17:243-64.
18. Nardone A, Decludt B, Jarraud S, et al. Repeat capture-recapture studies as part of the evaluation of the surveillance of Legionnaires' disease in France. Epidemiol Infect 2003; 131:647-54.
19. Palusci VJ, Wirtz SJ, Covington TM. Using capture-recapture methods to better ascertain the incidence of fatal child maltreatment. Child Abuse Negl 2010; 34:396-402.
20. Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol 2001; 154:1006-12.
21. Jhung MA, Swerdlow D, Olsen SJ, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011; 52(Suppl 1):S13-26.
22. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-12.
23. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, doubleblind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-76.
24. Sugaya N, Kohno S, Ishibashi T, et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza Avirus infection. Antimicrob Agents Chemother 2012; 56:369-77.
25. Sorbello A, Jones S, Carter WW, et al. Emergency Use Authorization for Intravenous Peramivir: Evaluation of Safety in the Treatment of Hospitalized Patients Infected with 2009 H1N1 Influenza A Virus. Clin Infect Dis 2012.
26. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011; 52(Suppl 1):S75-82.
27. Meyerhoff A, Lietman P. Losing the opportunity to study influenza drugs. JAMA 2010; 303:878-9.